Evidence map›Paper›PMID 35704533›Full record

ArticleThe Journal of clinical endocrinology and metabolism2022

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System.

Emanuel Raschi, Michele Fusaroli, Francesco Massari, Veronica Mollica, Andrea Repaci, Andrea Ardizzoni, Elisabetta Poluzzi, Uberto Pagotto, Guido Di Dalmazi

Open access · hybridAbstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Emanuel RaschiPharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna 40138, Italy.
Michele FusaroliPharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna 40138, Italy.
Francesco MassariMedical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
Veronica MollicaMedical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.ORCID 0000-0002-5169-3631
Andrea RepaciDivision of Endocrinology and Diabetes Prevention and Care Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
Andrea ArdizzoniMedical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
Elisabetta PoluzziPharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna 40138, Italy.
Uberto PagottoDivision of Endocrinology and Diabetes Prevention and Care Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.
Guido Di DalmaziDivision of Endocrinology and Diabetes Prevention and Care Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy.ORCID 0000-0002-1291-8906
Azienda USL di Bologna · ITUniversity of Bologna · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextAdrenal insufficiency (AI) is a life-threatening condition complicating heterogeneous disorders across various disciplines, with challenging diagnosis and a notable drug-induced component.

objectiveThis work aimed to describe the spectrum of drug-induced AI through adverse drug event reports received by the US Food and Drug Administration (FDA).

methodsA retrospective disproportionality analysis reporting trends of drug-induced AI was conducted on the FDA Adverse Event Reporting System (FAERS) (> 15 000 000 reports since 2004). AE reports were extracted from FAERS over the past 2 decades. Interventions included cases containing any of the preferred terms in the Medical Dictionary for Regulatory Activities describing AI, and signals of disproportionate reporting for drugs recorded in 10 or more cases as primary suspect.

resultsWe identified 8496 cases of AI: 97.5% serious, 41.1% requiring hospitalization. AI showed an exponential increase throughout the years, with 5282 (62.2%) cases in 2015 to 2020. We identified 56 compounds associated with substantial disproportionality: glucocorticoids (N = 1971), monoclonal antibodies (N = 1644, of which N = 1330 were associated with immune checkpoint inhibitors-ICIs), hormone therapy (N = 291), anti-infectives (N = 252), drugs for hypercortisolism or adrenocortical cancer diagnosis/treatment (N = 169), and protein kinase inhibitors (N = 138). Cases of AI by glucocorticoids were stable in each 5-year period (22%-27%), whereas those by monoclonal antibodies, largely ICIs, peaked from 13% in 2010 to 2015 to 33% in 2015 to 2020.

conclusionWe provide a comprehensive insight into the evolution of drug-induced AI, highlighting the heterogeneous spectrum of culprit drug classes and the emerging increased reporting of ICIs. We claim for the urgent identification of predictive factors for drug-induced AI, and the establishment of screening and educational protocols for patients and caregivers.

Indexed as

Adrenal InsufficiencyAntineoplastic Agents, ImmunologicalDrug-Related Side Effects and Adverse ReactionsAdverse Drug Reaction Reporting SystemsAntibodies, MonoclonalHumansRetrospective StudiesUnited StatesUnited States Food and Drug AdministrationAntibodies, MonoclonalAntineoplastic Agents, Immunologicaladrenal insufficiencycancercheckpointdrug-inducedFAERSFDAglucocorticoidiatrogenicimmune checkpoint inhibitorswithdrawal

Identifiers

PMID35704533
PMCPMC9282361
OpenAlexW4282970174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.